341 related articles for article (PubMed ID: 31984118)
1. Imaging response predictors following drug eluting beads chemoembolization in the neoadjuvant liver transplant treatment of hepatocellular carcinoma.
Galastri FL; Nasser F; Affonso BB; Valle LGM; Odísio BC; Motta-Leal Filho JM; Salvalaggio PR; Garcia RG; de Almeida MD; Baroni RH; Wolosker N
World J Hepatol; 2020 Jan; 12(1):21-33. PubMed ID: 31984118
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation.
Nicolini D; Svegliati-Baroni G; Candelari R; Mincarelli C; Mandolesi A; Bearzi I; Mocchegiani F; Vecchi A; Montalti R; Benedetti A; Risaliti A; Vivarelli M
World J Gastroenterol; 2013 Sep; 19(34):5622-32. PubMed ID: 24039354
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
[TBL] [Abstract][Full Text] [Related]
4. Radiological characteristics of hepatocellular carcinoma that achieved complete response after chemoembolization with drug-eluting beads for liver transplantation planning.
Valle LGM; Cunha MJS; Schmid BP; Falsarella PM; Rezende MB; Felga GEG; Ogawa RE; Garcia RG; Affonso BB; Nasser F; Galastri FL
Einstein (Sao Paulo); 2023; 21():eAO0307. PubMed ID: 37909650
[TBL] [Abstract][Full Text] [Related]
5. Does neoadjuvant doxorubicin drug-eluting bead transarterial chemoembolization improve survival in patients undergoing liver transplant for hepatocellular carcinoma?
Dorcaratto D; Udupa V; Hogan NM; Brophy DP; McCann JW; Maguire D; Geoghegan J; Cantwell CP; Hoti E
Diagn Interv Radiol; 2017; 23(6):441-447. PubMed ID: 29063856
[TBL] [Abstract][Full Text] [Related]
6. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
[TBL] [Abstract][Full Text] [Related]
7. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
8. Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma.
Greco G; Cascella T; Facciorusso A; Nani R; Lanocita R; Morosi C; Vaiani M; Calareso G; Greco FG; Ragnanese A; Bongini MA; Marchianò AV; Mazzaferro V; Spreafico C
World J Radiol; 2017 May; 9(5):245-252. PubMed ID: 28634515
[TBL] [Abstract][Full Text] [Related]
9. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinomas within the Milan criteria: predictors of histologic necrosis after drug-eluting beads transarterial chemoembolization.
Odisio BC; Galastri F; Avritscher R; Afonso BB; Segatelli V; Felga GE; Salvalaggio PR; Ensor J; Wallace MJ; Nasser F
Cardiovasc Intervent Radiol; 2014 Aug; 37(4):1018-26. PubMed ID: 24149832
[TBL] [Abstract][Full Text] [Related]
11. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation.
Nicolini D; Agostini A; Montalti R; Mocchegiani F; Mincarelli C; Mandolesi A; Robertson NL; Candelari R; Giovagnoni A; Vivarelli M
World J Gastroenterol; 2017 May; 23(20):3690-3701. PubMed ID: 28611522
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma.
Vesselle G; Quirier-Leleu C; Velasco S; Charier F; Silvain C; Boucebci S; Ingrand P; Tasu JP
Eur Radiol; 2016 Jun; 26(6):1640-8. PubMed ID: 26455721
[TBL] [Abstract][Full Text] [Related]
13. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
Ann Oncol; 2013 Apr; 24(4):965-73. PubMed ID: 23223331
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Treatment Response of Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma.
Adel H; Shazlee MK; Qamar S; Hyder SMS; Razaque A
Cureus; 2023 Jul; 15(7):e41701. PubMed ID: 37575777
[TBL] [Abstract][Full Text] [Related]
15. Survival and Outcome in Patients Receiving Drug-Eluting Beads Transarterial Chemoembolization for Large Hepatocellular Carcinoma (>5 cm).
Mukund A; Bhardwaj K; Choudhury A; Sarin SK
J Clin Exp Hepatol; 2021; 11(6):674-681. PubMed ID: 34866846
[TBL] [Abstract][Full Text] [Related]
16. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Huang K; Zhou Q; Wang R; Cheng D; Ma Y
J Gastroenterol Hepatol; 2014 May; 29(5):920-5. PubMed ID: 24224722
[TBL] [Abstract][Full Text] [Related]
18. Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization.
Choi MH; Park GE; Oh SN; Park MY; Rha SE; Lee YJ; Jung SE; Choi JI
Acad Radiol; 2018 Nov; 25(11):1363-1373. PubMed ID: 29555570
[TBL] [Abstract][Full Text] [Related]
19. Comparison of initial tumor responses to transarterial bland embolization and drug-eluting beads-transarterial chemoembolization in the management of hepatocellular carcinoma: a propensity-score matching analysis.
Guo J; Wang W; Zhang Y; Xu L; Kong J
J Gastrointest Oncol; 2021 Aug; 12(4):1838-1850. PubMed ID: 34532132
[TBL] [Abstract][Full Text] [Related]
20. Conventional TACE and drug-eluting bead TACE as locoregional therapy before orthotopic liver transplantation: comparison of explant pathologic response.
Frenette CT; Osorio RC; Stark J; Fok B; Boktour MR; Guy J; Rhee J; Osorio RW
Transplantation; 2014 Oct; 98(7):781-7. PubMed ID: 24825513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
